Inequities exist in receipt of preferred first-line therapies for patients with CLL

Key takeaways:

Significantly fewer Hispanic patients received preferred first-line treatment for CLL vs. white patients.

Use of preferred first-line treatment also varied by practice type.

CHICAGO — Researchers observed inequities in receipt of first-line preferred therapies among a cohort of patients with chronic lymphocytic leukemia, according to results of a retrospective observational study.

The findings, presented at ASCO Annual Meeting, specifically showed disproportionate use of chemoimmunotherapy and ibrutinib (Imbruvica; Janssen, Pharmacyclics) by race/ethnicity, as well as differences in use of preferred targeted therapies by practice type and time period.

Use of preferred first-line treatment for CLL varied by race/ethnicity and practice type. Image: Adobe Stock.

Adam